Item 1.01. Entry into a Material
Definitive Agreement.
Registered Offering
On February 7, 2017, Real Goods Solar, Inc.
(the “Company”) priced a registered offering of (a) units, “Primary Units,” each consisting of one
share of the Company’s Class A common stock, par value $0.0001 (“Common Stock”), and a Series M Warrant
to purchase 75% of one share of Common Stock (the “Series M Warrant), and (b) units, “Alternative Units,”
each consisting of a prepaid Series N Warrant to purchase one share of Common Stock (the “Series N Warrants,”
and together with the Series M Warrants, collectively, the “Warrants”), and a Series M Warrant. Investors in the
offering entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the Company. The purchase
price for a Primary Unit is $2.50 and the purchase price for an Alternative Unit is $2.49. The Primary Units and the
Alternative Units are referred to in this Current Report on Form 8-K collectively as the “Units.”
In connection with pricing the offering, on February
7, 2017, the Company entered into the Purchase Agreement with 8 institutional and accredited investors
(the “Institutional Investors”). Several of the Institutional Investors have participated in the
Company’s past securities offerings and 4 of the Institutional Investors may be the beneficial owners of more than 5%
of the Common Stock based on a review of their filed Schedules 13G. Pursuant to the terms of the Purchase Agreement,
the Company will sell to the Institutional Investors an aggregate of approximately $4,125,000 of the Primary Units and
approximately $1,867,500 of the Alternative Units.
The closing of the offering is expected to occur on or about
February 9, 2017, subject to the satisfaction of certain customary closing conditions.
The Company offered and sold the Units, the shares of
Commons Stock and the Series M Warrants issued as part of the Primary Units, and the Series N Warrant and the Series M
Warrants issued as a part of the Alternative Units pursuant to an effective registration statement on Form S-3 (File No.
333-193718). In addition, the shares of Common Stock issuable upon exercise of the Warrants are also registered on the same
registration statement. In the Purchase Agreement, the Company has agreed to maintain an effective registration statement
covering the issuance of the Common Stock issuable upon exercise of the Warrants.
The Company expects to receive net proceeds of
approximately $5.5 million at the closing, after deducting commissions to the Placement Agent (as defined below) and
estimated offering expenses associated with the offering payable by the Company.
The Units will not be issued or certificated. The Series M
Warrants and the Series N Warrants, as applicable, will be issued in certificated physical form and may be transferred
separately immediately thereafter. The Warrants will not be listed on any national securities exchange or other trading
market, and no trading market for the Warrants is expected to develop.
Terms of the Series M Warrants
Each Primary Unit and Alternative Unit contains a Series
M Warrant to purchase 75% of one share of Common Stock. The Series M Warrants will be exercisable upon issuance and will
remain exercisable until the fifth anniversary of the date of issuance. The initial exercise price of the Series M Warrants
is $2.40 per share, subject to adjustments for stock splits and similar events. In addition, the Company may, with the
consent of the “required holders” (as defined in the Series M Warrants), reduce the then current exercise price
to any amount and for any period of time deemed appropriate by the Company’s board of directors. Under certain
circumstances, the holders of the Series M Warrants may elect to exercise them through a cashless exercise, in which case
the holders will receive upon such exercise the “net number” of shares of Common Stock determined according to
the formula set forth in the Series M Warrants and the Company will not receive the cash exercise price.
A holder may not exercise a Series M Warrant and we may not
issue shares of Common Stock under a Series M Warrant if, after giving effect to the exercise or issuance, the holder together
with its affiliates would beneficially own in excess of a set percentage of the outstanding shares of our Common Stock. The cap
will be set on the date of issuance at either 4.99% or 9.99%, at each holder’s election. If no election is made, the initial
cap will be set at 4.99%. At each holder’s option, the cap may be increased or decreased to any other percentage not in excess
of 9.99%, except that any increase will not be effective until the 61st day after notice to us.
The holders of the Series M Warrants are entitled to
acquire options, convertible securities or rights to purchase the Company’s securities or property granted, issued or
sold pro rata to the holders of its Common Stock on an “as if exercised for Common Stock” basis. The holders of
the Series M Warrants are entitled to receive any dividend or other distribution of the Company’s assets (or rights to
acquire its assets), at any time after the issuance of the Series M Warrants, on an “as if exercised for Common
Stock” basis. The Series M Warrants prohibit the Company from entering into transactions constituting a
“fundamental transaction” (as defined in the Series M Warrants) unless the successor entity assumes all of the
Company’s obligations under the Series M Warrants and the other transaction documents in a written agreement approved
by the “required holders” of the Series M Warrants. The definition of “fundamental transactions”
includes, but is not limited to, mergers, a sale of all or substantially all of the Company’s assets, certain tender
offers and other transactions that result in a change of control.
Terms of the Series N Warrants
The exercise price for a Series N Warrant will be paid at the
closing except for the further payment of the $0.01 exercise price per share, which a holder will pay upon exercise. The Series
N Warrants will have substantially the same terms as the Series M Warrants.
Additional Terms of the Purchase Agreement
The terms of the Purchase Agreement limit the Company’s
ability to issue securities in the future:
|
·
|
Until 90 days after the closing of the offering, the Company may not issue, enter into any agreement to issue or announce the
issuance or proposed issuance of any shares of Common Stock, or any security which would entitle the holder to acquire at any time
shares of Common Stock.
|
|
·
|
Until 90 days after the closing of the offering, the Company may not effect or enter into an agreement to effect any issuance
of shares of Common Stock or any security which would entitle the holder to acquire at any time shares of Common Stock involving
a Variable Rate Transaction (as defined in the Purchase Agreement). The term “Variable Rate Transaction” generally
means a transaction in which the Company issues or sells any debt or equity securities that are convertible into, exchangeable
or exercisable for, or include the right to receive, additional shares of Common Stock either (a) at a conversion price, exercise
price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the shares
of Common Stock at any time after the initial issuance of such debt or equity securities or (b) with a conversion, exercise or
exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or
upon the occurrence of specified or contingent events directly or indirectly related to the Company’s business or the market
for the Common Stock.
|
|
·
|
For one year after the closing of the offering, the Company may not effect or enter into an agreement to effect any issuance
of shares of Common Stock, or any security which would entitle the holder to acquire at any time shares of Common Stock, involving
an equity line of credit, an at-the-market offering (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended
(“Securities Act”), or similarly structured transactions whereby we may issue securities at a future determined price.
|
However, the limitations on securities issuances described
above do not apply to the issuance of: (a) shares of Common Stock or options to the Company’s employees, officers or
directors pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of
the Company’s board of directors or a majority of the members of a committee of non-employee directors established for
such purpose for services rendered to the Company; (b) the warrant the Company expects to issue to Roth Capital Partners, LLC
in connection with this offering; (c) securities upon the exercise, exchange or conversion of the securities sold in this
offering, the Series M Warrants, the Series N Warrants, the warrant the Company expects to issue to Roth Capital Partners,
LLC in connection with this offering, and/or other securities exercisable or exchangeable for or convertible into shares of
Common Stock issued and outstanding on the date the Company entered into the Purchase Agreement, subject to certain
limitations; (d) up to 250,000 shares of Common Stock issued pursuant to an exemption from registration under the Securities
Act to the lender, or any successor thereto, who is a party to any revolving credit facility outstanding prior to the date of
the Purchase Agreement; and (e) securities issued pursuant to acquisitions or strategic transactions approved by a majority
of the Company’s disinterested directors, subject to certain limitations, provided that none of the issuances listed
above are Variable Rate Transactions (other than with respect to the transactions described in clause (c) of this
paragraph).
The Purchase Agreement also contains customary representations,
warranties, covenants, including indemnifications, and closing conditions.
Leak-Out Agreement
Each Institutional Investor entered into separate and substantially similar leak-out agreements with us on
February 7, 2017. Under the leak-out agreements, during the period commencing on February 7, 2017 and ending February 22, 2017,
each Institutional Investor (together with certain of its affiliates) may not sell, dispose or otherwise transfer, directly or
indirectly (including, without limitation, any sales, short sales, swaps or any derivative transactions that would be equivalent
to any sales or short positions), on any trading day, shares purchased in this offering and the shares of Common Stock issuable
upon exercise of the Series M Warrants and the Series N Warrants in an amount more than a specified percentage of the trading volume
of the Common Stock on the principal trading market, subject to certain exceptions such as any actual “long” (as defined
in Regulation SHO of the Securities Exchange Act of 1934, as amended) sales at a price greater than $3.15. The aggregate trading
volume for all Institutional Investor is 35% of the trading volume of the Common Stock on the principal trading market during each
trading day during the above referenced leak-out period, subject to certain exception.
Placement Agent
Roth Capital Partners, LLC acted as the exclusive placement
agent for the offering (the “Placement Agent”) pursuant to the terms of a Placement Agency Agreement, dated February
7, 2017 (the “Placement Agency Agreement”). The Company’s engagement of the Placement Agent expires 15 days from
the date of the Placement Agency Agreement. In connection with the closing of the offering, the Company expects to pay the Placement
Agent a cash fee equal to approximately $419,475, an amount equal to 7% of the gross proceeds received by the Company from the
sale of the Units. The Company has agreed to reimburse Roth Capital Partners, LLC’s expenses up to a maximum of $75,000.
At the closing of the offering, the Company has agreed to
issue to the Placement Agent a warrant (the “Placement Agent Warrant”) to purchase up to a number of
shares of Common Stock equal to 5.0% of the aggregate number of shares of Common Stock issued at the closing and issuable
upon exercise of the Series N Warrants (exclusive of any shares of Common Stock issuable upon exercise of the Series M
Warrants). The Placement Agent Warrant will have substantially the same terms as the Series M Warrants other than that (a) it
will expire five years after the effective date of the offering; (b) it will be exercisable through a cashless exercise
regardless of whether the shares of Common Stock issuable upon exercise of the Placement Agent Warrant are covered by a
registration statement under the Securities Act; (c) the exercise price will be 125% of the public offering price per Primary
Unit; (d) certain covenants appearing in the Series M Warrants will be removed in the Placement Agent Warrant; and (e)
pursuant to FINRA Rule 5110(g), the Placement Agent Warrant, and the underlying securities, will not be transferable for 6
months from the date of issuance, except the transfer of any security: (i) by operation of law or by reason of reorganization
of the Company; (ii) to any FINRA member firm participating in the offering and the officers or partners thereof, if all
securities so transferred remain subject to the lock-up restriction set forth above for the remainder of the time period;
(iii) if the aggregate amount of securities of the Company held by the holder of the Placement Agent Warrant or related
persons do not exceed 1% of the securities being offered; (iv) that is beneficially owned on a pro-rata basis by all equity
owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund, and
participating members in the aggregate do not own more than 10% of the equity in the fund; or (v) the exercise or
conversion of any security, if all securities received remain subject to the lock-up restriction set forth above for the
remainder of the time period.
Additionally, the Company has agreed to indemnify the Placement
Agent against certain liabilities, including liabilities under the Securities Act or to contribute to payments the Placement Agent
may be required to make because of those liabilities.
The Placement Agency Agreement also contains customary representations,
warranties, covenants and closing conditions.
The descriptions of each of the Purchase Agreement, the Series
M Warrant, the Series N Warrant, the Leak-Out Agreement and the Placement Agency Agreement are qualified in their entirety by reference
to the forms attached hereto as Exhibits 10.1, 4.1, 4.2, 10.2 and 1.1, respectively.
Disclaimers of Representations and Warranties
The representations and warranties of the Company and its subsidiaries
contained in the Purchase Agreement and the Placement Agency Agreement have been made solely for the benefit of the parties thereto.
In addition, such representations and warranties (a) have been made only for purposes of such documents, (b) in some cases, have
been qualified by documents filed with, or furnished to, the Securities and Exchange Commission by the Company before the date
of the Purchase Agreement and the Placement Agency Agreement, (c) are subject to materiality qualifications contained therein which
may differ from what may be viewed as material by investors, (d) were made only as of the date of the Purchase Agreement and the
Placement Agency Agreement, or such other date as is specified in such documents, and (e) have been included in the Purchase Agreement
and the Placement Agency Agreement for the purpose of allocating risk between the contracting parties rather than establishing
matters as facts.
Accordingly, the Purchase Agreement and the Placement Agency
Agreement are included with this filing only to provide investors with information regarding the terms of such documents, and not
to provide investors with any other factual information regarding the Company or its subsidiaries or their respective business.
You should not rely on the representations and warranties or any descriptions thereof as characterizations of the actual state
of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter
of the representations and warranties may change after the date of the Purchase Agreement and the Placement Agency Agreement, which
subsequent information may or may not be fully reflected in the Company’s public disclosures. The Purchase Agreement and
Placement Agency Agreement should not be read alone, but should instead be read in conjunction with the other information regarding
the Company and its subsidiaries that has been, is or will be contained in, or incorporated by reference into, the Forms 10-K,
Forms 10-Q, Forms 8-K, proxy statements, registration statements and other documents that the Company files with the Securities
and Exchange Commission.
Forward-Looking Statements
This Current Report on Form 8-K includes forward-looking statements
relating to matters that are not historical facts. Forward-looking statements may be identified by the use of words such as “expect,”
“believe,” “will,” “should,” “would” or comparable terminology or by discussions
of strategy. While the Company believes its assumptions and expectations underlying forward-looking statements are reasonable,
there can be no assurance that actual results will not be materially different. Risks and uncertainties that could cause materially
different results include, among others, the Company’s ability to close the offering described herein and whether holders
of the Warrants will exercise them for cash and other risks and uncertainties included in the Company’s filings with the
Securities and Exchange Commission. The Company assumes no duty to update any forward-looking statements.
Item 1.02 Termination of a Material Definitive Agreement.
On February 6, 2017, Real Goods Solar, Inc. (the “Company”)
and its wholly-owned subsidiaries RGS Financing, Inc., Real Goods Energy Tech, Inc., Alteris Renewables, Inc., Real Goods Syndicated,
Inc., Mercury Energy, Inc., Real Goods Solar, Inc. – Mercury Solar, Elemental Energy, LLC and Sunetric Management LLC (collectively
with the Company, the “Borrower Parties”) gave notice to terminate the Amended and Restated Loan Agreement (as further
amended, the “Loan Agreement”), dated March 30, 2016, between the Borrower Parties and Solar Solutions and Distribution,
LLC, a Colorado-based renewable energy solutions company (“Solar Solutions”), effective February 9, 2017. The
Loan Agreement, which has a declining maximum borrow provision, as of January 1, 2017, provides for a $3,000,000 revolving line
of credit and matures by its terms on March 31, 2017. The Company has not drawn on this revolving line of credit for working
capital purposes since September 28, 2016 and does not have a current balance due to Solar Solutions under this revolving line
of credit.
In addition to being a lender to the Company, Solar Solutions also
supplies the Company with certain renewable energy products at a price mark-up under an Exclusive Master Supply Agreement dated
April 29, 2015 (as amended, the “Supply Agreement”). The term of the Supply Agreement is coterminous with the
term of the Loan Agreement and, as a result, the termination of the Loan Agreement also results in a termination of the Supply
Agreement.
The Company is not subject to any prepayment or termination payments,
or penalties in connection with the early termination of the Loan Agreement and the Supply Agreement.
The terms of the Loan Agreement and the Supply Agreement are set
forth in, and copies thereof are included as exhibits to, the Company’s Current Reports on Form 8-K filed on March 30, 2016,
May 27, 2016 and August 24, 2016.